HOME > BUSINESS
BUSINESS
- Ratio of Generic Name Prescribing Up 30% in 2 Doctor Surveys
June 22, 2012
- Takeda Files MAAs for 2 Fixed-Dose Alogliptin Combination Drugs in Europe
June 21, 2012
- Takeda to Terminate Development of Anti-HGF Antibody; Return Rights to Galaxy of the US
June 21, 2012
- Teijin Pharma to Build New Laboratory to Support Increased Feburic Production and New Drug Development
June 21, 2012
- IBL, Trans Genic to Create Joint Venture for Diagnostic Agent Development and Clinical Tests
June 21, 2012
- Daiichi Sankyo to Market Ranbaxy Products in Venezuela
June 21, 2012
- Kyowa Hakko Kirin Reports Significant Decrease in Off Time with Parkinson’s Disease Drug that is Currently Under Approval Review
June 20, 2012
- RDKK Aims at Sales of 55.5 Billion Yen in 2014 Driven by Personalized Medicine: President Ogasawara
June 20, 2012
- Concrete Price Negotiations to Get Underway by August or September: President Choufuku of Mediceo
June 19, 2012
- Nichi-Iko, Mitani Sangyo to Build New Plant in Toyama for APIs
June 19, 2012
- “Sales, Shares Will Follow” Tohoku ALC Opening: Mediceo President Choufuku
June 19, 2012
- DSP Obtains Approval for Antipsychotic Drug Latuda in Canada
June 19, 2012
- Pfizer Japan Top Choice in All Factors Doctors Consider Important When Prescribing Generics: QLife Survey
June 19, 2012
- Takeda to Cease Distribution of 13 former Wyeth Products, Except for Prevenar, BeneFIX, Enbrel
June 19, 2012
- [Data] Sales of Takeda’s Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Otsuka HD's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Astellas's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Daiichi Sankyo's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Eisai's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Mitsubishi Tanabe's Mainstay Products in FY2011
June 19, 2012
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…